Table 1. Characteristics of the studies included in the meta-analysis.
| First author | Year | Country | Ethnicity | Genotyping medthod | Source of control | Cancer type | Total sample size (case/control) | HWE | SNP |
|---|---|---|---|---|---|---|---|---|---|
| Sousa | 2016 | Brazil | Mixed | Taqman | hospital | HCC | 106/139 | 0.44 | rs1001179 |
| Castaldo | 2015 | Portugal | Caucasian | PCR | population | CC | 119/106 | 0.00 | rs1001179 |
| Geybels | 2015 | Netherland | Caucasian | PCR | population | PC | 1529/25184 | 0.00 | rs1001179 |
| Liu | 2015 | China | Asian | PCR-RFLP | hospital | HCC | 266/248 | 0.68 | rs1001179 |
| Saadat | 2015 | Iran | Caucasian | PCR | population | BC | 407/395 | 0.40 | rs1001179 |
| Su-1 | 2015 | China | Asian | PCR-RFLP | hospital | HCC | 301/186 | 0.49 | rs1001179 |
| Su-2 | 2015 | China | Asian | PCR-RFLP | hospital | HCC | 99/294 | 0.83 | rs1001179 |
| Banescu | 2014 | Romania | Caucasian | PCR-RFLP | population | CML | 168/321 | 0.47 | rs1001179 |
| Aynali | 2013 | Turkey | Caucasian | PCR-RFLP | hospital | Laryngeal cancer | 25/23 | 0.13 | rs1001179 |
| Tefik | 2013 | Turkey | Caucasian | PCR-RFLP | population | PC | 155/195 | 0.07 | rs1001179 |
| Ding | 2012 | China | Asian | PCR | population | PC | 1417/1008 | 0.86 | rs1001179 |
| Farawela | 2012 | Egypt | Caucasian | PCR-RFLP | population | NHL | 100/100 | 0.49 | rs1001179 |
| Karunasinghe | 2012 | New Zealand | Mixed | Taqman | population | PC | 258/567 | 0.42 | rs1001179 |
| Tsai | 2012 | Taiwan | Asian | PCR | hospital | BC | 260/224 | 0.44 | rs1001179 |
| Chang | 2012 | China | Asian | PCR-RFLP | population | CRC | 880/848 | 0.00 | rs794316 |
| Nahon | 2011 | France | Caucasian | Taqman | hospital | HCC | 84/55 | 0.62 | rs1001179 |
| Ezzikouri | 2010 | France | Mixed | PCR-RFLP | population | HCC | 96/222 | 0.59 | rs1001179 |
| He-1 | 2010 | USA | Caucasian | Taqman | population | BCC | 270/796 | 0.89 | rs1001179 |
| He-2 | 2010 | USA | Caucasian | Taqman | population | Melanoma | 211/796 | 0.89 | rs1001179 |
| He-3 | 2010 | USA | Caucasian | Taqman | population | SCC | 266/796 | 0.89 | rs1001179 |
| Tang | 2010 | USA | Mixed | Taqman | population | Pancreatic cancer | 551/602 | 0.97 | rs1001179 |
| Wu | 2010 | Taiwan | Asian | PCR-RFLP | hospital | OCC | 122/122 | 0.18 | rs794316 |
| Funke | 2009 | Germany | Caucasian | PCR | population | CRC | 632/605 | 0.11 | rs1001179 |
| Li | 2009 | USA | Caucasian | Taqman | population | BC | 497/493 | 1.00 | rs1001179 |
| Quick-1 | 2008 | USA | Caucasian | HM L/I MS | population | BC | 569/974 | 0.70 | rs1001179 |
| Quick-2 | 2008 | USA | Mixed | HM L/I MS | population | BC | 47/108 | 0.22 | rs1001179 |
| Rajaraman-1 | 2008 | USA | Caucasian | Taqman | hospital | Glioma | 330/438 | 0.57 | rs1001179 |
| Rajaraman-2 | 2008 | USA | Caucasian | Taqman | hospital | Meningioma | 120/438 | 0.57 | rs1001179 |
| Rajaraman-3 | 2008 | USA | Caucasian | Taqman | hospital | Acoustic neuroma | 63/438 | 0.57 | rs1001179 |
| Choi-1 | 2007 | USA | Caucasian | HM L/I MS | population | PC | 463/1233 | 0.26 | rs1001179 |
| Choi-2 | 2007 | USA | African | HM L/I MS | population | PC | 27/120 | 0.60 | rs1001179 |
| Cebrian | 2006 | UK | Caucasian | Taqman | population | BC | 2171/2262 | 0.96 | rs1001179 |
| Ho | 2006 | China | Asian | PCR-RFLP | hospital | LC | 230/240 | 0.44 | rs1001179 |
| Lightfoot | 2006 | USA/UK | Mixed | Taqman | population | NHL | 909/1437 | 0.96 | rs1001179 |
| Ahn | 2005 | USA | Caucasian | HM L/I MS | population | BC | 1008/1056 | 0.93 | rs1001179 |
| Lee-1 | 2002 | South Korea | Asian | PCR-RFLP | population | GC | 80/108 | 0.47 | rs794316 |
| Lee-2 | 2002 | South Korea | Asian | PCR-RFLP | population | HCC | 106/108 | 0.47 | rs794316 |
PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; HM L/I MS: high-throughput, matrixassisted, laser desorption/ionization time-of-flight mass spectrometry; HCC: hepatocellular carcinoma; CC: cervical cancer; BC: breast cancer; CML: chronic myeloid leukemia; NHL: non-Hodgkin lymphoma; BCC: basal cell carcinoma; SCC: squamous cell carcinoma; PC: Prostate cancer; CRC: colorectal cancer; OCC: Oral cavity cancer; GC: gastric cancer; LC: lung cancer; SNP: single-nucleotide polymorphisms; HWE: Hardy-Weinberg equilibrium.